News
FDA Approves Revumenib as Therapy for Relapsed or Refractory AML
Pune, India | October 27, 2025 The U.S. Food and Drug Administration (FDA) recently approved revumenib, an innovative oral menin inhibitor, to treat relapsed or
Read More